利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.017 秒)

    FORMULATIONS COMPRISING TRIPTAN COMPOUNDS
    1.
    发明申请
    FORMULATIONS COMPRISING TRIPTAN COMPOUNDS 有权

    公开(公告)号：US20230025210A1

    公开(公告)日：2023-01-26

    申请号：US17750354

    申请日：2022-05-22

    申请人： UPSHER-SMITH LABORATORIES, LLC

    发明人： Rajesh GANDHI ,  Sreekanth MANIKONDA ,  Arun JANA ,  Sameer Shrinivas KUNTE

    IPC分类号： A61K31/4045 ,  A61K31/40 ,  A61K31/70 ,  A61K45/06 ,  A61K31/404 ,  A61K9/00 ,  A61K31/7028 ,  A61K47/26

    摘要： The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described.
    The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

    METHODS OF TREATING MIGRAINE
    2.
    发明申请
    METHODS OF TREATING MIGRAINE 有权

    公开(公告)号：US20220096438A1

    公开(公告)日：2022-03-31

    申请号：US17273811

    申请日：2019-09-06

    申请人： Upsher-Smith Laboratories, LLC

    发明人： Sagar Munjal ,  Arun Jana

    IPC分类号： A61K31/4045 ,  A61K9/00 ,  A61P25/06

    摘要： The present application relates to a method of reducing a need of rescue medication and/or a need of more than one dose of migraine medication in a patient suffering from cephalic pain, including migraine, cluster headache, episodic migraine, or rapid escalating migraine. In some embodiments, the method includes administering intranasally a composition comprising sumatriptan, or a physiologically-acceptable salt or a solvate thereof, and an alkyl glycoside or a saccharide alkyl ester.

    Formulations comprising triptan compounds
    8.
    发明授权
    Formulations comprising triptan compounds 有权

    公开(公告)号：US11337962B2

    公开(公告)日：2022-05-24

    申请号：US16796494

    申请日：2020-02-20

    申请人： UPSHER-SMITH LABORATORIES, LLC

    发明人： Rajesh Gandhi ,  Sreekanth Manikonda ,  Arun Jana ,  Sameer Shrinivas Kunte

    IPC分类号： A61K31/4045 ,  A61K9/00 ,  A61K31/40 ,  A61K31/70 ,  A61K31/404 ,  A61K31/7028 ,  A61K45/06 ,  A61K47/26

    摘要： The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described.
    The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

    Formulations comprising triptan compounds
    9.
    发明授权
    Formulations comprising triptan compounds 有权

    公开(公告)号：US10603305B2

    公开(公告)日：2020-03-31

    申请号：US15924881

    申请日：2018-03-19

    申请人： UPSHER-SMITH LABORATORIES, LLC

    发明人： Rajesh Gandhi ,  Sreekanth Manikonda ,  Arun Jana ,  Sameer Shrinivas Kunte

    IPC分类号： A61K31/4045 ,  A61K31/40 ,  A61K31/70 ,  A61K31/404 ,  A61K31/7028 ,  A61K9/00 ,  A61K45/06 ,  A61K47/26

    摘要： The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described.The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.